Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Up 5.1 %

Shares of OGEN opened at $1.04 on Thursday. Oragenics has a one year low of $0.97 and a one year high of $7.74. The firm has a market cap of $4.66 million, a P/E ratio of -0.12 and a beta of 0.58. The stock has a 50 day simple moving average of $1.61.

Oragenics (NYSE:OGEN) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.